Exploring Systemic Therapies for Advanced Hepatocellular Carcinoma

This chapter examines the progression of systemic treatment options for advanced Hepatocellular Carcinoma (HCC) from the era predating 2008 with seraphanib to the more recent approval of lymphatinib based on the Reflect trial, illustrating advancements in response rates and time to progression.